News & Updates
Showing Oncology articles
Showing
Show Multimedia Only

SBRT shows slightly lower late GI and GU toxicities than conventional RT in prostate cancer
24 Sep 2026
byKanas Chan
Stereotactic body radiotherapy (SBRT) provides comparable 5-year biochemical progression-free survival (PFS) and is associated with slightly lower rates of gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional radiotherapy (RT) in Chinese patients with low- to intermediate-risk prostate cancer, according to a real-world study in Hong Kong.
24 Sep 2026

OCEAN II: Encorafenib + binimetinib of consistent efficacy and safety in Chinese and global NSCLC patients
24 Sep 2026
byNatalia Reoutova
Encorafenib plus binimetinib’s efficacy, safety and pharmacokinetics are consistent between Chinese patients and the global population, according to the results of the ongoing OCEAN II phase II trial in metastatic non-small-cell lung cancer (NSCLC) with BRAFV600E mutation.
24 Sep 2026






